PPT-Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer

Author : danika-pritchard | Published Date : 2019-02-13

ASCOCAP Recommendations For HER2 Testing in Breast Cancer Criteria For Reporting HER2 Test Results as Positive Criteria for Reporting HER2 Test Results as Negative

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Updates on the Use of Adjuvant Therapy i..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer: Transcript

ASCOCAP Recommendations For HER2 Testing in Breast Cancer Criteria For Reporting HER2 Test Results as Positive Criteria for Reporting HER2 Test Results as Negative Criteria for Reporting Equivocal Results . Leisha. A. . Emens. , M.D., . Ph.D. Associate Professor . of Oncology . Tumor . Immunology and Breast . Cancer . Research . Programs. Johns Hopkins University. Conflict of Interest Statement. Biosante. Clinical Practice Guideline Update. American Society of Clinical Oncology /. College of American Pathologists . www.asco.org/guidelines/. © American . Society of Clinical Oncology®. All rights reserved.. Joyce O'Shaughnessy, MD. Kimberly Blackwell, MD. Hope . Rugo. , MD. Reminder: feedback is appreciated. You will be prompted at the end for your feedback.. Updates on Chemotherapy and Other Novel Agents. Monica Brown, MPH, PhD. . California Cancer Registry. Mary Paré, RN, BS. . Sutter Cancer Center, Sacramento. Katrina Bauer, MS, CTR. . California Cancer Registry. NAACCR 2009 Conference, June 13-19, San Diego. Clinical Practice Guideline Update. American Society of Clinical Oncology /. College of American Pathologists . www.asco.org/guidelines/. © American . Society of Clinical Oncology®. All rights reserved.. Mohammad . Jahanzeb. , MD, FACP. Professor of Clinical Medicine, Hematology-Oncology. Director, UM Sylvester Deerfield Campus. Associate Center Director for Community Outreach. Sylvester Comprehensive Cancer Center. Dr. . Khaled Abulkhair, PhD. Medical Oncology SCE, Royal College, UK. Ass. Professor of Clinical Oncology. Mansoura University, Egypt. A long Road Searching for optimum Neo-Adjuvant Therapy in Her -2 Positive Breast Cancer. Rajiv Doddamani. . PGY – 3, Internal Medicine . . St. Joseph Mercy Ann Arbor . Learning objectives . Explain the principles of breast cancer screenings . Key Issues. Etienne GC . Brain. , MD . PhD. Institut Curie. Saint-Cloud, France. 1. www.siog.org. etienne.brain@curie.fr. Most common shortcut in statistics . . “1 in 8 women will develop BC in their lifetime”. Luminal B-like (HER2-positive):!ER-positive!HER2-positive!Any Ki67 ** Aggressive phenotypes: TNBC or HER2-positive breast cancer!If ChTis planned, it should all be given as neoadjuvant"Concomitant pos in Development for . Breast Cancer. Sara A. Hurvitz, MD, FACP. Professor of Medicine. David Geffen School of Medicine, UCLA. Los Angeles, CA. William J. Gradishar, MD, FASCO, FACP. Betsy Bramsen Professor of Breast Oncology & Professor of Medicine. Azeez Farooki, MD. Attending Physician, Clinical Member. Memorial Sloan Kettering Cancer Center. New York, NY. Objectives. Elucidate the problem of aromatase inhibitor induced bone loss and increased risk of fractures in breast cancer. Percent with Patients. Number of Patients (Median). ER-positive, HER2-negative breast cancer for whom you ordered a genomic assay. 92. 14. Metastatic ER-positive, HER2-negative . breast cancer. 96. 10. breast. . cancer. . needs. . different. . therapeutic. . strategies. . than. HER-2 . enriched. . tumors. ?. Patrizia Vici. Cleopatra. TDM-1: . EMILIA. Verma. S ESMO 2012. (. Activity. . HR+.

Download Document

Here is the link to download the presentation.
"Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.